Spotlight On... Taiwan's JHL teams up with Affinita; BioOutsource clears FDA inspection; and more...

Taiwanese contractor JHL Biotech signed a deal to help Affinita Biotech develop and manufacture antibody treatments for cancer, lining up for as much as $20 million over four years. Under the agreement, JHL will handle cell line development, manufacturing assistance and process development through its facilities in Taiwan and Wuhan, China. Affinita, headquartered in South San Francisco, is at work on preclinical therapies for a range of cancers. More

> Scottish service provider BioOutsource said its biologics-focused lab passed FDA inspection. News

> Trial tech firms DrugDev and Exostar are pairing up to co-market their services, offering a cloud-based data management product. Item

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.